1
TÍTULO: Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir plus dasabuvir +/- ribavirin in the TOPAZ-I and TOPAZ-II trials
AUTORES: Fred Poordad; Rui Sarmento E Castro; Armen Asatryan; Humberto Aguilar; Patrice Cacoub; Douglas Dieterich; Rui Marinho; Armando Carvalho; Asma Siddique; Yiran R Hu; Mariem Charafeddine; Mark Bondin; Nader Khan; Daniel Cohen; Franco Felizarta;
PUBLICAÇÃO: 2019, FONTE: International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL) in JOURNAL OF HEPATOLOGY, VOLUME: 70
INDEXADO EM: WOS
2
TÍTULO: ENDURANCE-2: Safety and Efficacy of ABT-493/ABT-530 in Hepatitis C Virus Genotype 2-infected Patients without Cirrhosis, a Randomized, Double-Blind, Placebo-Controlled Study  Full Text
AUTORES: Kris V Kowdley; Massimo Colombo; Neddie Zadeikis; Parvez S Mantry; Filipe Calinas; Humberto I Aguilar; Victor de Ledinghen; Yves J Horsmans; Yiran R Hu; Teresa Ng; Federico Mensa;
PUBLICAÇÃO: 2016, FONTE: 67th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) in HEPATOLOGY, VOLUME: 64
INDEXADO EM: WOS